Is the price fair?
What NAMS's price assumes
NewAmsterdam Pharma Company N.V. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 173× revenue.
173
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 5.86
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 5.86
- EV / EBIToperating margin −954%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $3.49B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.